Moreover, patients with an unmethylated promoter for the gene encoding O6-methylguanine-DNA methyltransferase (MGMT) had a more aggressive prognosis and resistance to temozolomide,7 with a median progression-free survival (PFS) of 5.3 to 6.9 months in patients with GBM. Here, MGMT is linked to glioblastoma.